Drug intelligence / Profile preview

autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes

Development stage: Unknown
Lead developer: Novartis
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes is a type of chimeric antigen receptor T-cell (CAR-T) therapy that uses a patient's own T cells engineered to express a receptor targeting CD19, a protein found on B cells. This CAR construct contains a 4-1BB costimulatory domain and CD3zeta signaling domain, along with a truncated epidermal growth factor receptor (EGFRt) as a safety mechanism. Upon administration, these modified T cells recognize and attack CD19-positive cells, making them effective against B-cell malignancies including leukemias and lymphomas.

Targets

CD19 (B lymphocyte antigen CD19)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes.

Explore the full profile